Outlook: the profit problem in antibiotic R&D
Related Experiment Video
Updated: Aug 15, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
Published on: October 17, 2019
Carl Nathan1, Frederick M Goldberg
1Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, New York 10021, USA. cnathan@med.cornell.edu
Abstract:
Economists, a biomedical researcher and a business executive have formulated three contrasting proposals to address the shortfall in antibiotic R&D. Their proposals, which emphasize advance purchase contracts, not-for-profit research, and tax incentives, respectively, share some features with provisions in bills pending before the US Congress that could potentially reshape the R&D landscape for this essential class of drugs.
More Related Videos
09:09High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
Published on: November 16, 2016
10:29A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Related Concept Videos
Production of Antibiotics
Antibiotic Selection
Mechanism of Antibiotic Resistance in MRSA
Development of Antibiotic Resistance
Clinical Significance of Antibiotic Resistance
Production of Pharmaceuticals